Comparison of periodontal ligament and gingiva-derived mesenchymal stem cells for regenerative therapies

Santamaría, Silvia Santamaría; Sánchez, Nerea; Sanz, Mariano; García‐Sanz, Jose A.

doi:10.1007/s00784-016-1867-3

Cited by 29 publications

(27 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Human GMSCs are homogenous, not tumorigenic [97], and easy to be isolated [98] and display stable phenotype. The most significant advantage of human GMSCs is without any ethical problems in clinical application [99].…”

Section: Mscs Derived From Other Tissuesmentioning

confidence: 99%

Mesenchymal Stem Cells Improve Healing of Diabetic Foot Ulcer

Cao

Gang

Wang

2017

Journal of Diabetes Research

137

119

View full text Add to dashboard Cite

Mesenchymal stem cells (MSCs), an ideal cell source for regenerative therapy with no ethical issues, play an important role in diabetic foot ulcer (DFU). Growing evidence has demonstrated that MSCs transplantation can accelerate wound closure, ameliorate clinical parameters, and avoid amputation. In this review, we clarify the mechanism of preclinical studies, as well as safety and efficacy of clinical trials in the treatment of DFU. Bone marrow-derived mesenchymal stem cells (BM-MSCs), compared with MSCs derived from other tissues, may be a suitable cell type that can provide easy, effective, and cost-efficient transplantation to treat DFU and protect patients from amputation.

show abstract

Section: Mscs Derived From Other Tissuesmentioning

confidence: 99%

Mesenchymal Stem Cells Improve Healing of Diabetic Foot Ulcer

Cao

Gang

Wang

2017

Journal of Diabetes Research

137

119

View full text Add to dashboard Cite

show abstract

“…Gingival fibroblasts were found to express variable levels of mRNA for alkaline phosphate and bone morphogenetic protein 2/4 (BMP2/4) in vitro, which demonstrated that appropriate stimuli may direct their capacity of hard tissue formation [8]. By the same token, gingival mesenchymal stem/progenitor cells (GMSCs), with self-renewal capabilities, remarkable differentiation potential, long-term telomerase expression, and outstanding immunomodulatory properties have been isolated [9,10]. GMCSs preconditioned in an osteogenic differentiation medium demonstrated on the mRNA level expression of bone specific markers, including Runx2, collagen I, collagen III, ALP, osteonectin (ON), osteopontin (OP), osteocalcin (OC), and osterix [9].…”

Section: Introductionmentioning

confidence: 99%

“…GMCSs preconditioned in an osteogenic differentiation medium demonstrated on the mRNA level expression of bone specific markers, including Runx2, collagen I, collagen III, ALP, osteonectin (ON), osteopontin (OP), osteocalcin (OC), and osterix [9]. GMSCs showed few inflammation-related changes when incubated with proinflammatory mediators (TNF-α, IL-1β), which suggested good response to unfavorable environmental conditions [10]. A bone regenerative capacity of GMSCs has been confirmed by multiple studies, as these cells were able to repair the critical size mandibular/calvarial defects in animals [11][12][13].…”

Section: Introductionmentioning

confidence: 99%

Treatment of intrabony defects with modified perforated membranes in aggressive periodontitis: a 12-month randomized controlled trial

et al. 2018

View full text Add to dashboard Cite

Objective The aim of this study was to compare the clinical and radiographic efficacy of guided tissue regeneration with a modified perforated collagen membrane (MPM) or standard collagen membrane (CM) in the treatment of intrabony defects in patients with aggressive periodontitis (AgP). Materials and methods Fifteen AgP patients were included in the study. Two single intrabony defects of at least 3 mm depth with ≥ 6 mm probing pocket depth (PPD) from each patient were randomly assigned to either xenogenic graft plus MPM (test group) or xenogenic graft plus CM (control group). PPD, clinical attachment level (CAL), and gingival recession (GR) were recorded at baseline and at 12 months. The radiographic assessments included the measurements of defect depth (DD), change in alveolar crest position (ACP), linear defect fill (LDF), and percentage defect fill (%DF). Results After treatment, PPD, CAL, DD, and ACP values improved significantly in both groups, without statistical differences between them. However, with respect to LDF and %DF, the 12-month radiographic analysis at MPM-treated sites showed a significant improvement compared to the 6-month outcomes, that was not observed at control sites (additional LDF of 0.4 ± 0.5 mm, p = 0.010 and %DF of 6.4 ± 7.6%, p = 0.025). Conclusions Both strategies proved effective in the treatment of intrabony defects in patients with AgP. Nonetheless, enhanced LDF and %DF 12 months postoperatively at MPM-treated sites may stem from cellular and molecular migration from the periosteum and overlying gingival connective tissue through barrier's pores. Clinical relevance Modification of CM may have positive ramifications on periodontal regeneration.

show abstract

“…These results agree with other studies devoted to gingival MMSC that reported similar phenotype characteristics, differentiation potential and stable genomic behavior. 19,39,40 Also, we determined high proliferative capacity of AMC which remained constant from primary to long-term cultures. It should be noted that the population doubling time for bone marrowderived MMSC reaches only 55 § 3 hours under similar cultivation conditions.…”

Section: Discussionmentioning

confidence: 99%

“…10 It was described earlier that MMSC derived from different tissues can possess various colony-forming unit and differentiation efficiency as well as different proliferative capacity. 19,20,21 Another important issue is availability of the source tissue, namely invasiveness of manipulation and risk of complications, related to sample procurement. 22 Gingival mucosa is one of promising sources of MMSC due to availability and minimally invasiveness of its procurement and ability of gingival mucosa wounds to heal without formation of scar.…”

Section: Introductionmentioning

confidence: 99%

Myogenic potential of human alveolar mucosa derived cells

et al. 2017

View full text Add to dashboard Cite

Difficulties related to the obtainment of stem/progenitor cells from skeletal muscle tissue make the search for new sources of myogenic cells highly relevant. Alveolar mucosa might be considered as a perspective candidate due to availability and high proliferative capacity of its cells. Human alveolar mucosa cells (AMC) were obtained from gingival biopsy samples collected from 10 healthy donors and cultured up to 10 passages. AMC matched the generally accepted multipotent mesenchymal stromal cells criteria and possess population doubling time, caryotype and immunophenotype stability during long-term cultivation. The single myogenic induction of primary cell cultures resulted in differentiation of AMC into multinucleated myotubes. The myogenic differentiation was associated with expression of skeletal muscle markers: skeletal myosin, skeletal actin, myogenin and MyoD1. Efficiency of myogenic differentiation in AMC cultures was similar to that in skeletal muscle cells. Furthermore, some of differentiated myotubes exhibited contractions in vitro. Our data confirms the sufficiently high myogenic potential and proliferative capacity of AMC and their ability to maintain in vitro proliferation-competent myogenic precursor cells regardless of the passage number.

show abstract

Comparison of periodontal ligament and gingiva-derived mesenchymal stem cells for regenerative therapies

Abstract: Gingiva-derived MSCs may represent an accessible source of messenchymal stem cells to be used in future periodontal regenerative therapies.

Cited by 29 publications

References 46 publications

Mesenchymal Stem Cells Improve Healing of Diabetic Foot Ulcer

Mesenchymal Stem Cells Improve Healing of Diabetic Foot Ulcer

Treatment of intrabony defects with modified perforated membranes in aggressive periodontitis: a 12-month randomized controlled trial

Myogenic potential of human alveolar mucosa derived cells

Contact Info

Product

Resources

About